Table 1
Open in new tab

Prioritization algorithm for biomarker-based targeted treatment

GroupCriterion
1Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit − with moderate survival benefit or inconsistent
2ABiomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma
2BBiomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting
3AClinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation − amp/ expression
3BClinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation − amp/expression
GroupCriterion
1Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit − with moderate survival benefit or inconsistent
2ABiomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma
2BBiomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting
3AClinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation − amp/ expression
3BClinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation − amp/expression
Table 1
Open in new tab

Prioritization algorithm for biomarker-based targeted treatment

GroupCriterion
1Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit − with moderate survival benefit or inconsistent
2ABiomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma
2BBiomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting
3AClinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation − amp/ expression
3BClinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation − amp/expression
GroupCriterion
1Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit − with moderate survival benefit or inconsistent
2ABiomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma
2BBiomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting
3AClinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation − amp/ expression
3BClinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation − amp/expression
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close